Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Besides antiretroviral therapy, 9/168 patients (5.4%) were taking calcium supplementation, and 91/168 (54.2%) were already taking adequate vitamin D supplementation.Comparison between patients with normal BMD, osteopenia and osteoporosis, and between patients with vertebral fractures vs patients without vertebral fracturesTotal(n. 168)Normal valuesNormal BMD(n. 21)Osteopenia(n. 89)Osteoporosis(n. 58)P valueNo vertebral fractures (n. 126)Vertebral fractures(n. 42)P valueAge (years)53 (46 to 60)54 (49 to 57)52 (49 to 57)0.84052 (48 to 57)55 (51 to 60)0.048BMI (kg/m2)25.2 (22.7 to 28.7)*25.7 (23 to 27.9)*22.7 (20.8 to 25.9)**0.00125.0 (22.3 to 27.2)24.6 (21.1 to 27.1)0.477SmokeCurrent smoker, # (%)6/18 (33.3)29/72 (40.3)30/44 (68.2)0.02745/100 (45)20/34 (58.8)0.271Past smoker, # (%)3/18 (16.7)11/72 (15.3)2/44 (4.5)14/100 (14)2/34 (5.9)AlcoholUsual drinker, # (%)3/18 (16.7)21/68 (30.9)12/44 (27.3)0.71525/95 (26.3)11/35 (31.4)0.785Occasional drinker, # (%)10/18 (55.6)30/68 (44.1)18/44 (40.9)44/95 (46.3)14/35 (40)Drug user, # (%)5/20 (25)20/77 (26)27/51 (52.9)0.00434/111 (30.6)18/37 (48.6)0.047HIV infection duration (years)11 (6 to 20.5)*11.5 (6 to 20)*17 (10.5 to 24.5)**0.03511 (8 to 20)18 (9 to 25)0.015cART duration (years)11 (5 to 16.5)8.5 (5 to 16.8)13 (8.8 to 18)0.08710 (7 to 16)14 (7.5 to 18)0.002CD4 + nadir (cell/mm3)190 (62 to 325.5)173 (55.5 to 287.5)120 (52 to 248)0.523150 (59 to 292)127.5 (48.5 to 223)0.300CD4 + nadir (%)18.9 (11.6 to 22.9)14.9 (8.7 to 22.1)14 (7.7 to 22.6)0.53314.9 (8.3 to 22.2)15.2 (9.7 to 22.1)0.987CD4 + at inclusion (cell/mm3)470 to 1240731 (534 to 960)675 (457 to 799)560 (412 to 755.5)0.160643 (442 to 808)596 (381.3 to 886.5)0.697CD4 + at inclusion (%)31.0 to 58.032.8 (24.9 to 38)31.8 (25.5 to 37.9)29.6 (21.7 to 34.9)0.32631.5 (23.9 to 37.8)32.1 (25.2 to 35.7)0.799AIDS, # (%)5/21 (23.8)24/81 (29.6)16/52 (30.8)0.83431/116 (26.7)14/38 (36.8)0.234HBsAg + , # (%)1/21 (4.8)5/79 (6.3)5/54 (9.3)0.7328/116 (6.9)3/38 (7.9)0.836HCV Ab + , # (%)7/21 (33.3)27/81 (33.3)30/52 (57.7)0.01544/116 (37.9)20/38 (52.6)0.111Diabetic, # (%)3/21 (14.3)12/89 (13.5)8/58 (13.8)0.99516/126 (12.7)7/42 (16.7)0.515Chronic kidney disease, # (%)1/21 (4.8)6/89 (6.7)4/58 (6.9)0.9397/126 (5.6)4/42 (9.5)0.368Hypogonadism, # (%)4/19 (21.1)22/83 (26.5)18/53 (34)0.48229/119 (24.4)15/36 (41.2)0.044Type of hypogonadismPrimary, # (%)1/4 (25)2/21 (9.5)2/16 (12.5)0.7644/28 (14.3)1/13 (7.7)0.526Secondary, # (%)1/4 (25)10/21 (47.6)5/16 (31.3)12/28 (42.9)4/13 (30.8)Compensated, # (%)2/4 (50)9/21 (42.8)9/16 (56.3)12/28 (42.9)8/13 (61.5)TT (ng/ml)3 to 96.2 (4.8 to 7.5)6.6 (5.2 to 8.5)7 (5.3 to 9.3)0.2416.6 (5.2 to 8.4)6.9 (5.1 to 9.1)0.438SHBG (nmol/l)10 to 7049 (41.2 to 60.5)*64 (43.5 to 92)69.5 (51.8 to 94.5)*0.03459.0 (42.7 to 73.0)84.5 (56.8 to 113.8)0.010cFT (pg/ml)65 to 26098.9 (80.6 to 118)93.6 (73.6 to 119.3)94.3 (71.9 to 117.8)0.85994.9 (74.1 to 115.3)88.6 (72.0 to 119.0)0.825LH (IU/l)1.5 to 9.03.6 (2.9 to 7.9)6.3 (3.6 to 8.2)6 (4 to 13.5)0.0795.2 (3.3 to 8.2)7.5 (4.1 to 10.7)0.085FSH (IU/l)1.5 to 85.2 (4.1 to 6.2)6.9 (3.8 to 10.3)6.8 (4.9 to 11.3)0.2205.9 (4.1 to 9.5)6.8 (4.7 to 12.7)0.322Calcium, serum (mg/dl)8.6 to 10.29.3 (8.8 to 9.7)9.2 (9 to 9.6)9.4 (9.2 to 9.6)0.2049.3 (9.0 to 9.7)9.3 (9.1 to 9.5)0.994Calcium, 24 h urine (mg/24 h)100 to 300226.6 (163.5 to 314)221 (156 to 327)212.5 (122.6 to 297.8)0.570223.3 (158.0 to 315.0)201.5 (141.5 to 300.5)0.592Phosphate, serum (mg/dl)2.5 to 4.32.4 (2.1 to 2.7)2.6 (2.2 to 3)2.5 (2.2 to 3.2)0.2832.5 (2.2 to 2.9)2.8 (2.5 to 3.3)0.003Phosphate, 24 h urine (mg/24 h)400 to 1300816.5 (732.8 to 1059.5)910.8 (715.7 to 1138.5)810 (578 to 1066)0.363912.5 (730.1 to 1116.3)738.0 (552.5 to 918.0)0.010PTH (pg/ml)11 to 6741.8 (32.8 to 76)48 (32 to 67)51 (39 to 63)0.93245.0 (34.0 to 70.0)50.0 (40.8 to 60.3)0.77425-OH-vitamin D (ng/ml) > 2032 (26.2 to 39.5)28.5 (18.9 to 38.5)33 (19.3 to 42)0.40129.5 (19.2 to 36)34.5 (23.2 to 48.7)0.068Bone alkaline phosphatase (IU/l)10 to 5032 (22.2 to 51.8)34 (27 to 50.5)39 (31 to 60)0.35738.0 (29.0 to 52.0)32.0 (20.0 to 58.0)0.163C-terminal telopeptide (ng/ml)0.1 to 0.70.4 (0.2 to 0.5)0.5 (0.3 to 0.6)0.4 (0.2 to 0.7)0.8020.5 (0.3 to 0.6)0.3 (0.2 to 0.5)0.266Osteocalcin (ng/ml) < 209 (5.9 to 17)9 (5.3 to 16.3)11.4 (7 to 19.7)0.38010.0 (7.0 to 16.5)9.0 (5.0 to 17.8)0.655Spine BMD (g/cm2)1.2 (1.1 to 1.2)**1 (0.9 to 1.1)**0.8 (0.7 to 0.9)** < 0.0011 (0.9 to 1.1)0.9 (0.8 to 1)0.021Spine T-score (SD)0.2 (: 0.6; 0.5)**: 1.4 (: 1.8;: 1)**: 2.9 (: 3.5;: 2.7)** < 0.001 to 1.5 (: 2.5;: 0.8): 2.3 (: 3;: 1.3)0.017Total hip BMD (g/cm2)1.1 (1 to 1.1)**0.9 (0.8 to 1)**0.8 (0.7 to 0.9)** < 0.0010.9 (0.8 to 1.1)0.8 (0.7 to 0.9)0.021Total hip T-score (SD)0 (: 0.5; 0.4)**: 1 (: 1.5;: 0.3)**: 1.8 (: 2.4;: 1.2)** < 0.001 to 0.9 (: 1.5;: 0.1): 1.5 (: 2.4;: 1.1)0.001Femoral neck BMD (g/cm2)1 (0.9 to 1) **0.8 (0.7 to 0.9)**0.7 (0.6 to 0.8)** < 0.0010.8 (0.7 to 0.9)0.8 (0.7 to 0.8)0.091Femoral neck T-score (SD): 0.3 (: 0.8; 0)**: 1.3 (: 1.8;: 1)**: 2.1 (: 2.7;: 1.6)** < 0.001 to 1.2 (: 1.9;: 0.7): 1.8 (: 2.2;: 1.3) < 0.001Vertebral fractures, # (%)1/21 (4.8)**19/89 (21.3)**22/58 (37.9)**0.006///Variables expressed as median (IQR) or absolute number (%) as appropriateComparisons for continuous variables are performed with Kruskal: Wallis, for BMD comparison, and with Mann: Whitney U test, for vertebral fractures comparison (post hoc: Bonferroni, identified in table through*).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were defined as current smokers if actively smoking at least 1 cigarette/day, and past smokers if they had quit smoking for at least one year.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men

Study design awaiting verification · Journal of Endocrinological Investigation · 2021

Original publication title

Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men

L. C. Pezzaioli; T. Porcelli; A. Delbarba; F. Maffezzoni; E. Focà; F. Castelli; C. Cappelli; A. Ferlin; M. E. Quiros-Roldan

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We found a high burden of bone disease and hypogonadism in HIV-infected men, and we showed that the impact of gonadal function on bone health is more evident on VFs than on BMD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Hypogonadism and osteoporosis are frequently reported in HIV-infected men and, besides multifactorial pathogenesis, they might be directly linked because of testicular involvement in bone health. We evaluated the prevalence of osteoporosis and vertebral fractures (VFs) in HIV-infected men, and assessed their relationship with gonadal function.

Source: Purpose

Abstract: What methods does the paper describe?

We enrolled 168 HIV-infected men (median age 53). Osteoporosis and osteopenia were defined with T-score ≤: 2.5SD and T-score between: 1 and: 2.5SD, respectively. VFs were assessed by quantitative morphometric analysis. Total testosterone (TT), calculated free testosterone (cFT), Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) were obtained; overt hypogonadism was defined on symptoms and low TT or cFT, and classified into primary and secondary according to gonadotropins; compensated hypogonadism was defined as normal TT and cFT with high LH levels.

Source: Methods

Abstract: Results

Overall, osteoporosis and osteopenia were found in 87.5% of patients, and VFs were detected in 25% of them; hypogonadism was identified in 26.2% of cases. Osteoporotic patients had higher SHBG vs those with normal bone mineral density (BMD). Fractured patients were more frequently hypogonadal and with higher SHBG. SHBG showed negative correlation with both spine and femoral BMD, and positive correlation with VFs. In multivariate models, FSH showed negative impact only on femoral BMD, whereas older age and higher SHBG predicted VFs.

Source: Results

Abstract: Conclusion

We found a high burden of bone disease and hypogonadism in HIV-infected men, and we showed that the impact of gonadal function on bone health is more evident on VFs than on BMD.

Source: Conclusion
Authors’ abstract

Purpose

Hypogonadism and osteoporosis are frequently reported in HIV-infected men and, besides multifactorial pathogenesis, they might be directly linked because of testicular involvement in bone health. We evaluated the prevalence of osteoporosis and vertebral fractures (VFs) in HIV-infected men, and assessed their relationship with gonadal function.

Methods

We enrolled 168 HIV-infected men (median age 53). Osteoporosis and osteopenia were defined with T-score ≤: 2.5SD and T-score between: 1 and: 2.5SD, respectively. VFs were assessed by quantitative morphometric analysis. Total testosterone (TT), calculated free testosterone (cFT), Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) were obtained; overt hypogonadism was defined on symptoms and low TT or cFT, and classified into primary and secondary according to gonadotropins; compensated hypogonadism was defined as normal TT and cFT with high LH levels.

Results

Overall, osteoporosis and osteopenia were found in 87.5% of patients, and VFs were detected in 25% of them; hypogonadism was identified in 26.2% of cases. Osteoporotic patients had higher SHBG vs those with normal bone mineral density (BMD). Fractured patients were more frequently hypogonadal and with higher SHBG. SHBG showed negative correlation with both spine and femoral BMD, and positive correlation with VFs. In multivariate models, FSH showed negative impact only on femoral BMD, whereas older age and higher SHBG predicted VFs.

Conclusion

We found a high burden of bone disease and hypogonadism in HIV-infected men, and we showed that the impact of gonadal function on bone health is more evident on VFs than on BMD.

Publication and source details

Original title: Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men

L. C. Pezzaioli; T. Porcelli; A. Delbarba; F. Maffezzoni; E. Focà; F. Castelli; C. Cappelli; A. Ferlin; M. E. Quiros-Roldan

Journal of Endocrinological Investigation · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Brescia

Open access funding provided by Università degli Studi di Brescia within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T11:50:40.032545+00:00

DOI: 10.1007/s40618-021-01665-7 · PMC8783890